TORONTO, Feb. 23 /PRNewswire/ - Trillium Therapeutics Inc. (TTI)
announced today that Dr. Michael Moore, Chief Executive Officer of PIramed,
has joined TTI's Board of Directors.
"The addition of Dr. Moore to TTI's Board of Directors is another
important step in the company's quest to assemble strong and well-balanced
leadership that blends global industry veterans with experienced investors,"
explained Dr. Niclas Stiernholm, TTI's Chief Executive Officer. "We are very
pleased to welcome such a seasoned biotechnology executive as Michael to the
TTI team. His impressive scientific credentials, vast drug development
experience, and far-reaching networks in both industry and academia, make him
a superb addition to TTI's already high-quality Board."
Dr. Moore is currently Chief Executive Officer and Director of PIramed
Ltd, a privately held UK-based biotechnology company focused on the discovery
and development of drugs targeting members of the PI3 kinase super-family. He
is also an Associate Professor at the Brunel Institute of Cancer Genetics and
Pharmacogenomics. Prior to joining PIramed, he held several progressive
positions (1988-2003), including Chief Scientific Officer and Research
Director, at Xenova Group plc, a publicly traded biotechnology company. Dr.
Moore has held a series of academic appointments at Christie Hospital,
Paterson Institute for Cancer Research and University of Manchester, which
included a tenured Cancer Research Campaign Appointment as well an Honorary
Readership in Immunology and Oncology at University of Manchester Medical
School. He received his Ph.D. and D.Sc. degrees from Nottingham University and
has more than 150 scientific publications.
Trillium also announced that Dr. Bob Uger has been promoted to Vice
President, Research & Development effective February 1, 2004.
TTI, a privately held Research and Development (R&D) company, specializes
in the development of innovative therapies that restore balance to the immune
system in conditions associated with aberrant and harmful immune responses,
such as autoimmune and inflammatory disorders, graft rejection and viral
hepatitis. The Company identifies therapeutic candidates with promising
preclinical profiles and advances these into clinical testing, with the
primary objective of demonstrating safety and efficacy in humans. The Company
has two lead development candidates, a CD200 fusion protein (CD200Fc) and an
Fgl2-specific monoclonal antibody (Fgl2 Mab). TTI has a variety of external
R&D collaborations, including several with major pharmaceutical and
SOURCE Trillium Therapeutics Inc.